Medifast, Inc.

MED

US58470H1014

Food Processing

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
33.71 ^USD	+0.63%		+3.91%	-49.85%

Feb. 20	Medifast, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 20	Transcript : Medifast, Inc., Q4 2023 Earnings Call, Feb 20, 2024

Tranche Update on Medifast, Inc.'s Equity Buyback Plan announced on December 9, 2013.

November 06, 2023 at 04:50 pm EST

From July 1, 2023 to September 30, 2023, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 2,676,432 shares, representing 22.34% for $287.61 million under the buyback announced on December 9, 2013.

Latest news about Medifast, Inc.

Medifast, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 20	CI
Transcript : Medifast, Inc., Q4 2023 Earnings Call, Feb 20, 2024	Feb. 20
Earnings Flash (MED) MEDIFAST Posts Q4 EPS $1.09, vs. Street Est of $0.96	Feb. 20	MT
Earnings Flash (MED) MEDIFAST Reports Q4 Revenue $191M, vs. Street Est of $184.2M	Feb. 20	MT
Medifast Provides Earnings Guidance for the First Quarter of 2024	Feb. 20	CI
Medifast, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 20	CI
Health Care Climbs After Fed Policy Move -- Health Care Roundup	Dec. 13	DJ
Medifast, LifeMD Collaborate to Offer Weight Management Solution; Medifast Scraps Quarterly Dividend	Dec. 13	MT
Transcript : LifeMD, Inc., Medifast, Inc. - Special Call	Dec. 13
Medifast's Board of Directors Elect to Discontinue the Company's Quarterly Cash Dividend	Dec. 13	CI
Medifast Initiates Business Transformation by Entering the Medically Supported Weight Loss Market through Collaboration with LifeMD, Inc	Dec. 13	CI
Tranche Update on Medifast, Inc.'s Equity Buyback Plan announced on December 9, 2013.	Nov. 06	CI
Medifast, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Transcript : Medifast, Inc., Q3 2023 Earnings Call, Nov 06, 2023	Nov. 06
Earnings Flash (MED) MEDIFAST Posts Q3 Revenue $235.9M, vs. Street Est of $232.1M	Nov. 06	MT
Medifast, Inc. Provides Earnings Guidance for the Full Year 2023	Nov. 06	CI
Stephens Initiates Medifast With Equalweight Rating, Price Target is $82	23-10-13	MT
Medifast Unveils Supplements for Muscle Health	23-09-14	MT
Medifast, Inc. Announces Optavia Active Now Available	23-09-13	CI
Medifast Keeps Quarterly Dividend at $1.65 a Share, Payable Nov. 7 to Shareholders of Record Sept. 19	23-09-07	MT
Medifast, Inc. Declares Quarterly Cash Dividend, Payable on November 7, 2023	23-09-07	CI
Insider Sell: Medifast	23-08-16	MT
Medifast Q2 Net Income, Revenue Fall; Q3 Outlook Set -- Shares Jump After-Hours	23-08-07	MT
Tranche Update on Medifast, Inc.'s Equity Buyback Plan announced on December 9, 2013.	23-08-07	CI
Transcript : Medifast, Inc., Q2 2023 Earnings Call, Aug 07, 2023	23-08-07

Chart Medifast, Inc.

Duration

Period

More charts

Company Profile

Medifast, Inc. is a health and wellness company. The Company provides a habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a comprehensive approach to help them achieve lasting optimal health and wellbeing. OPTAVIA's lifestyle plans deliver clinically proven health benefits as well as evidence-based tools, including scientifically developed products and a framework for habit creation reinforced by independent coaches and community support. Through a collaboration with the virtual primary care provider LifeMD, Inc (LifeMD), OPTAVIA customers have access to board-certified affiliated clinicians and medications, such as GLP-1s, that support treatment plans for obesity and other health conditions. OPTAVIA Coaches introduce customers to a set of healthy habits, and offer OPTAVIA-branded products, including Fuelings as well as OPTAVIA ACTIVE, a line of essential amino acid supplements and protein powders. Its operations are conducted through its subsidiaries.

Sector

Food Processing

Calendar

2024-04-28 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Medifast, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

33.71 USD

Average target price

37.5 USD

Spread / Average Target

+11.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Special Foods & Wellbeing Products

	1st Jan change	Capi.
MEDIFAST, INC.	-49.85%	363M
ZHEJIANG NHU COMPANY LTD.	+8.20%	7.78B
BELLRING BRANDS, INC.	+0.34%	7.38B
CSPC INNOVATION PHARMACEUTICAL CO., LTD.	+10.20%	6.52B
BYHEALTH CO., LTD	-8.10%	3.67B
THE SIMPLY GOOD FOODS COMPANY	-13.13%	3.44B
XIAMEN KINGDOMWAY GROUP COMPANY	-14.57%	1.17B
SIRIO PHARMA CO., LTD.	+8.34%	934M
HERBALIFE LTD.	-42.27%	879M
USANA HEALTH SCIENCES, INC.	-18.90%	836M

Special Foods & Wellbeing Products

Medifast, Inc.

Equities

MED

US58470H1014

Food Processing

Tranche Update on Medifast, Inc.'s Equity Buyback Plan announced on December 9, 2013.

EPS Revisions